Literature DB >> 21704022

Recent advances in gene manipulation and nicotinic acetylcholine receptor biology.

Anne Tammimäki1, William J Horton, Jerry A Stitzel.   

Abstract

Pharmacological and immunological methods have been valuable for both identifying some native nicotinic acetylcholine receptor (nAChR) subtypes that exist in vivo and determining the neurobiological and behavioral role of certain nAChR subtypes. However, these approaches suffer from shortage of subtype specific ligands and reliable immunological reagents. Consequently, genetic approaches have been developed to complement earlier approaches to identify native nAChR subtypes and to assess the contribution of nAChRs to brain function and behavior. In this review we describe how assembly partners, knock-in mice and targeted lentiviral re-expression of genes have been utilized to improve our understanding of nAChR neurobiology. In addition, we summarize emerging genetic tools in nAChR research.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21704022      PMCID： PMC3162071          DOI： 10.1016/j.bcp.2011.06.014

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN： 0006-2952            Impact factor:   5.858


  113 in total

1.  Chimeric analysis of a neuronal nicotinic acetylcholine receptor reveals amino acids conferring sensitivity to alpha-bungarotoxin.

Authors:  M M Levandoski; Y Lin; L Moise; J T McLaughlin; E Cooper; E Hawrot
Journal:  J Biol Chem       Date:  1999-09-10       Impact factor: 5.157

2.  The actions of nicotine on central nervous system functions.

Authors:  H SILVETTE; E C HOFF; P S LARSON; H B HAAG
Journal:  Pharmacol Rev       Date:  1962-03       Impact factor: 25.468

3.  Nicotinic acetylcholine receptors containing the α4 subunit are critical for the nicotine-induced reduction of acute voluntary ethanol consumption.

Authors:  Linzy M Hendrickson; Paul Gardner; Andrew R Tapper
Journal:  Channels (Austin)       Date:  2011-03-01       Impact factor: 2.581

4.  Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial.

Authors:  Douglas E Jorenby; J Taylor Hays; Nancy A Rigotti; Salomon Azoulay; Eric J Watsky; Kathryn E Williams; Clare B Billing; Jason Gong; Karen R Reeves
Journal:  JAMA       Date:  2006-07-05       Impact factor: 56.272

5.  Effect of the alpha4beta2* nicotinic acetylcholine receptor partial agonist varenicline on dopamine release in beta2 knock-out mice with selective re-expression of the beta2 subunit in the ventral tegmental area.

Authors:  Christelle Reperant; Stéphanie Pons; Eric Dufour; Hans Rollema; Alain M Gardier; Uwe Maskos
Journal:  Neuropharmacology       Date:  2009-11-01       Impact factor: 5.250

6.  Chicken neuronal acetylcholine receptor alpha 2-subunit gene exhibits neuron-specific expression in the brain and spinal cord of transgenic mice.

Authors:  P Daubas; A M Salmon; M Zoli; B Geoffroy; A Devillers-Thiéry; A Bessis; F Médevielle; J P Changeux
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-15       Impact factor: 11.205

7.  Expression changes in mouse brains following nicotine-induced seizures: the modulation of transcription factor networks.

Authors:  Merav Kedmi; Avi Orr-Urtreger
Journal:  Physiol Genomics       Date:  2007-04-24       Impact factor: 3.107

8.  Rodent habenulo-interpeduncular pathway expresses a large variety of uncommon nAChR subtypes, but only the alpha3beta4* and alpha3beta3beta4* subtypes mediate acetylcholine release.

Authors:  Sharon R Grady; Milena Moretti; Michele Zoli; Michael J Marks; Alessio Zanardi; Luca Pucci; Francesco Clementi; Cecilia Gotti
Journal:  J Neurosci       Date:  2009-02-18       Impact factor: 6.167

Review 9.  Mammalian nicotinic acetylcholine receptors: from structure to function.

Authors:  Edson X Albuquerque; Edna F R Pereira; Manickavasagom Alkondon; Scott W Rogers
Journal:  Physiol Rev       Date:  2009-01       Impact factor: 37.312

10.  Optogenetics.

Authors:  Karl Deisseroth
Journal:  Nat Methods       Date:  2010-12-20       Impact factor: 28.547
View more
  6 in total

1.  Neurochemistry: Lighting up with azobenzenes.

Authors:  G Andrew Woolley
Journal:  Nat Chem       Date:  2012-01-24       Impact factor: 24.427

2.  Cotinine conundrum--a step forward but questions remain.

Authors:  Margaret R Spitz; Christopher I Amos; Laura J Bierut; Neil E Caporaso
Journal:  J Natl Cancer Inst       Date:  2012-04-25       Impact factor: 13.506

3.  AAV-directed persistent expression of a gene encoding anti-nicotine antibody for smoking cessation.

Authors:  Martin J Hicks; Jonathan B Rosenberg; Bishnu P De; Odelya E Pagovich; Colin N Young; Jian-ping Qiu; Stephen M Kaminsky; Neil R Hackett; Stefan Worgall; Kim D Janda; Robin L Davisson; Ronald G Crystal
Journal:  Sci Transl Med       Date:  2012-06-27       Impact factor: 17.956

Review 4.  Genetic matters: thirty years of progress using mouse models in nicotinic research.

Authors:  Michael J Marks
Journal:  Biochem Pharmacol       Date:  2013-06-06       Impact factor: 5.858

5.  Nicotine inhibits memory CTL programming.

Authors:  Zhifeng Sun; Kendra Smyth; Karla Garcia; Elliot Mattson; Lei Li; Zhengguo Xiao
Journal:  PLoS One       Date:  2013-07-02       Impact factor: 3.240

Review 6.  Bridging the clinical gaps: genetic, epigenetic and transcriptomic biomarkers for the early detection of lung cancer in the post-National Lung Screening Trial era.

Authors:  John F Brothers; Kahkeshan Hijazi; Celine Mascaux; Randa A El-Zein; Margaret R Spitz; Avrum Spira
Journal:  BMC Med       Date:  2013-07-19       Impact factor: 8.775
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.